Cure SMA Launches “Spotlight on SMA” Partnership with Neurology Reviews

Leave a Comment / Front Page News, Our Impact, Research /

Cure SMA is pleased to announce the release of “Spotlight on SMA: The Urgent Need for Early Diagnosis in Spinal Muscular Atrophy,” a supplement developed in collaboration with Neurology Reviews. The goal of this partnership is to enhance current awareness and understanding of SMA diagnostic requirements, while emphasizing the importance of early treatment as it […]

Cure SMA Launches “Spotlight on SMA” Partnership with Neurology Reviews Read More »

Celebrate Rare Disease Day 2020 with Cure SMA

Leave a Comment / Community Awareness, Front Page News /

This year, Rare Disease Day occurs on February 29—the rarest day of all! Spinal muscular atrophy (SMA) affects 12,000 people in the U.S. Yet, the SMA community is part of a greater community—the rare disease community—that comprises of 300 million people worldwide. Together, we create an even stronger voice to raise awareness and educate others

Celebrate Rare Disease Day 2020 with Cure SMA Read More »

Lights…Camera…Action! Search Is On for Child with SMA to Appear in NBC Television Pilot

Leave a Comment / Community Awareness, Front Page News /

Cure SMA is excited to support casting directors from NBC as they search for boys and girls from the SMA community who are interested in playing a character with spinal muscular atrophy in an upcoming 20th Century Fox pilot. The team is currently focusing their search on children aged 7-11 years of age in the Chicagoland

Lights…Camera…Action! Search Is On for Child with SMA to Appear in NBC Television Pilot Read More »

Genentech’s Risdiplam Showed Significant Improvement in Motor Function in People Aged 2-25 Years with Type 2 or Type 3 SMA

Leave a Comment / Clinical Trials, Front Page News, Research /

Genentech, a member of the Roche Group, today presented 1-year data from the pivotal Part 2 of the SUNFISH study, evaluating risdiplam in people aged 2-25 years with Type 2 or Type 3 spinal muscular atrophy (SMA). The study showed that change from baseline in the primary endpoint of the Motor Function Measure 32 scale

Genentech’s Risdiplam Showed Significant Improvement in Motor Function in People Aged 2-25 Years with Type 2 or Type 3 SMA Read More »

Cure SMA Adds New Equipment Item for Teens and Adults with SMA

Leave a Comment / Front Page News, Support & Care /

Along with funding SMA research and offering clinical care services, Cure SMA provides thousands of affected individuals and families with vital support and resources that help them navigate daily life with SMA. We are thrilled to add to our equipment pool inventory the Panthera S3 Swing—a lightweight manual wheelchair for adults and teens living with

Cure SMA Adds New Equipment Item for Teens and Adults with SMA Read More »

Genentech’s Risdiplam Meets Primary Endpoint in Pivotal FIREFISH Trial in Infants with Type 1 SMA

Leave a Comment / Clinical Trials, Front Page News, Research /

Genentech, a member of the Roche Group, today announced positive topline results from the pivotal Part 2 of the FIREFISH study, evaluating risdiplam in infants aged 1-7 months with Type 1 spinal muscular atrophy (SMA). The primary outcome measure of the study was the proportion of infants sitting without support for at least five seconds

Genentech’s Risdiplam Meets Primary Endpoint in Pivotal FIREFISH Trial in Infants with Type 1 SMA Read More »

Annual SMA Conference Registration Continues to Grow!

Leave a Comment / Conference, Front Page News /

The 2020 Annual SMA Conference registration numbers are growing quickly! We expect the 2020 conference – which includes both the Family Conference and the Research & Clinical Care Meeting – will be one of our biggest ever. Hotel rooms in our block are filling up, so be sure to register and make your hotel reservations

Annual SMA Conference Registration Continues to Grow! Read More »

Community Statement from Scholar Rock Regarding SRK-015

Leave a Comment / Clinical Trials, Community Awareness, Front Page News /

Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today highlighted key accomplishments of the past year and announced R&D priorities for 2020. Below please find a community statement from Scholar Rock specifically discussing SRK-015. ______________________________________________________________________________ Dear SMA Community, We at Scholar

Community Statement from Scholar Rock Regarding SRK-015 Read More »

Cure SMA and Biogen to Co-Host Webinar on DEVOTE Clinical Trial – Register Today!

Leave a Comment / Clinical Trials, Front Page News, Research /

On Tuesday, February 4th, at 11am CST (9am PST/10am MST/12pm EST) Biogen and Cure SMA will co-host a webinar for the SMA community. During the webinar, you’ll hear from Biogen about the latest information on its SPINRAZA clinical trial, DEVOTE, a Phase 2/3 randomized, controlled dose-escalating study with infantile and later-onset SMA of all ages,

Cure SMA and Biogen to Co-Host Webinar on DEVOTE Clinical Trial – Register Today! Read More »

Scroll to Top